News
5h
Zacks Investment Research on MSNBioNTech SE Sponsored ADR (BNTX) Is Up 4.81% in One Week: What You Should KnowMomentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell ...
List today: Mission Produce, Inc. AVO: This fruits producer has seen the Zacks Consensus Estimate for its current year ...
The race to develop effective cancer vaccines has entered a new phase, with late-stage trials from companies like Moderna ...
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 29th: GDS Holdings Limited GDS: This data center operator from China has a Zacks Rank #1 ...
An expert panel of the EU drug regulator, the European Medicines Agency (EMA) on Friday recommended marketing authorizations ...
BioNTech (BNTX) is a stock many investors are watching right now. BNTX is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A. We should also highlight that BNTX has a P/B ratio of 1.21.
Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.
BNTX's current P/B looks attractive when compared to its industry's average P/B of 3.18. Over the past year, BNTX's P/B has been as high as 16.35 and as low as 1.70, with a median of 3.01.
BioNTech SE (NASDAQ:BNTX) is not the least popular stock in this group but hedge fund interest is still below average. Our overall hedge fund sentiment score for BNTX is 57.4.
Therefore, BNTX stock's valuation seems in line with its peers now. As a result of its fat coffers from the COVID-19 vaccine, BNTX is accelerating through its pipelines.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results